Search Results for “Janssen” – Page 3 – media

Janssen buys into Legend’s CART therapy

Janssen has entered into a global collaboration and license agreement with Legend Biotech USA and Legend Biotech Ireland to develop, manufacture and commercialise experimental CART-cell therapy LCAR-B38M.
- Source: Pharmatimes
- 412
- December 26, 2017
CAR-T therapy Company Insight Market Views
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer

Janssen Biotech, Inc. (Janssen) announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review designation for the New Drug Application (NDA) for apalutamide, an investigational, next-generation oral androgen receptor (AR) inhibitor for the treatment of men with non-metastatic castration-resistant prostate cancer (CRPC). Currently, there are no FDA-approved treatments for patients with non-metastatic CRPC.
- Source: Janssen
- 489
- December 25, 2017
CRPC inhibitor New Approvals
Johnson&Johnson Global Vice President Resigns

After optimizing the overall structure of Ziqiang Sheng, personnel change messages often occur. Recently, Larry Jones, Global Vice President of Medical Technology and Group Chief Information Officer at Johnson&Johnson, announced his decision to resign. He will retire from Johnson&Johnson Medical Devices, and details such as when he will officially resign or who will take over are still unknown. 35 year veteran resigns, Johnson&Johnson personnel changes frequently Larry Jones is an experienced veteran at Johnson&Johnson Medical, having served for 35 years. During his tenure at Johnson&Johnson’s Medical Devices division, Larry Jones was particularly dedicated to driving innovation in the fields of oncology, orthopedics, cardiovascular and general surgery, and revolutionizing digital surgical connectivity solutions through advanced technologies such as surgical robots and machine learning platforms. Larry Jones has served as the trans regional global CIO of Janssen Pharmaceuticals for more than six years. He is the executive member of the Johnson African ...
- Source: drugdu
- 69
- November 9, 2024
The World’s First Targeted Innovative Drug for Hepatitis B Approved for Market

On October 30, Xi’an Xintong Pharmaceutical Research Co., Ltd. held a press conference in the Silk Road Innovation and Smart Valley of Xi’an High-tech Zone to announce the approval of “Xinshi Mu,” a first-class innovative drug targeting hepatitis B. It is the commercial name approved for the drug Preadfovir mesylate tablets, which is indicated for the treatment of chronic hepatitis B in adults. The drug utilizes the HepDirect liver-targeted delivery system to concentrate the active ingredients in the target organ, enhancing efficacy and reducing toxicity. This makes it the world’s first approved liver-targeted innovative drug for hepatitis B. Zhang Denge, chairman of Xintong Pharmaceutical, stated that “Xinshi Mu” is part of the national major new drug creation projects during the 12th and 13th Five-Year Plans, with research beginning in 2011, and it took 13 years to gain approval for market release. Wang Liping, the Drug Safety Director of the Shaanxi ...
- Source: drugdu
- 48
- November 6, 2024
Johnson&Johnson announces latest personnel changes

Recently, Larry Jones, Global Vice President and Group Chief Information Officer of Medical Technology at Johnson&Johnson (NYSE: JNJ), will leave the world’s second-largest medical device manufacturer. He will retire from Johnson&Johnson’s medical device business. The details of when and when the official resignation will take place, or who will take over, are still unknown. 01. Retirement of Group Chief Information Officer Recently, Larry Jones announced that he will retire from Johnson&Johnson’s medical device business. When asked when he will officially resign or if someone will replace him, he said he will share more details when the information becomes public. Johnson&Johnson Medical Technology did not respond to further information requests. Jones is a goal oriented leader who achieves transformational change through key principles such as business process integration, agile methods, and next-generation technology solutions. He focuses on driving digital surgical connectivity solutions for Johnson&Johnson’s oncology, orthopedics, cardiovascular, and general surgery robots ...
- Source: drugdu
- 49
- November 5, 2024
Over 3 billion, Stone Pharmaceutical Group reached a major cooperation

On September 29, Shi Pharma Group signed an exclusive licensing agreement with Jiangsu Conri Pharma on the development and commercialization of JSKN003 in mainland China. JSKN003 is a HER2-targeting bispecific antibody-drug conjugate (ADC) with dual HER2 targeting, giving it stronger internalization induction and bystander killing effects, making it highly active against HER2-expressing tumors. Currently, JSKN003 is undergoing Phase I clinical trials in Australia and Phase I/II and Phase III clinical trials in China. Next, Jinmant Bio (a wholly-owned subsidiary of Chiatai Tianqing Pharmaceutical Group) will be granted exclusive license and sublicensing rights for the development, sales, promised sales, and commercialization of the product. They will bear all clinical development costs and become the sole marketing authorization holder for JSKN003 in Mainland China for that field. According to the agreement, Corning Jerry has the right to receive a total of up to 3.08 billion RMB in upfront and milestone payments, including ...
- Source: https://mp.weixin.qq.com
- 98
- October 2, 2024
Former President of Johnson & Johnson Orthopedics jumps to orthopedic giant!

Johnson & Johnson has had frequent executive changes in recent years, not only in the innovative pharmaceutical industry, but also in the medical technology department. At least nine executive changes have been reported since 2023. Recently, Enovis, a global orthopedic giant, announced the appointment of Tim Czartoski as president of its U.S. surgical and global products and supporting technologies business. Tim Czartoski previously worked in the DePuy Synthes orthopedic business unit of Johnson & Johnson Medical Technology. Tim Czartoski is a very experienced veteran in the medical field. He has more than 20 years of experience in the medical technology industry, especially in the orthopedic business. Tim Czartoski has held several key positions at Johnson & Johnson, leading the growth of Johnson & Johnson’s business. Looking back at Tim Czartoski’s career at Johnson & Johnson, he has held several positions in the DePuy Synthes orthopedic business unit of Johnson & ...
- Source: drugdu
- 76
- September 21, 2024
FDA Awards Accelerated Approval to Gilead Sciences Drug for Rare Liver Disease

Livdelzi is now FDA-approved for treating the rare liver disease primary biliary cholangitis. Gilead Sciences added the drug to its pipeline via the $4.3 billion acquisition of CymaBay Therapeutics earlier this year. By Frank Vinluan A Gilead Sciences drug acquired earlier this year in a multi-billion dollar deal is now FDA approved as new treatment for primary biliary cholangitis (PBC), a rare liver disease that can lead to liver failure. The approval announced Wednesday for the drug covers the treatment of adults whose disease is inadequately managed by the standard of care PBC drug as well as those who cannot tolerate that drug. The Gilead therapy, seladelpaar, will be marketed under the brand name Livdelzi. PBC is a rare, progressive autoimmune condition that leads to inflammation and scarring of the liver’s bile ducts. The chronic disorder, which impairs liver function, mainly strikes women over 40 years of age. Gilead estimates that ...
- Source: drugdu
- 77
- August 16, 2024
Chinese CAR-T Pioneer Legend Biotech in Profile

Chinese player Legend Biotech reached a new turning point last month when its Johnson & Johnson-partnered Carvykti became the first BCMA-targeted CAR-T cell therapy to be approved by the FDA for second-line treatment of multiple myeloma. From its original roots in China to its first FDA approval in 2022, the company has remained uniquely focused on CAR-T cells targeting the BCMA protein. Humble Beginnings and a Breakthrough Approval Back in 2014, a team of Chinese scientists began investigating cell therapies for cancer under the banner of the “Legend Project,” operating in what the company calls “a room the size of a freight elevator.” After making the decision to focus its research solely on chimeric antigen-receptor T-cells (CAR-T) targeting the BCMA protein in 2015, Legend began conducting its first clinical trials in 2016. The pioneering biotech landed its first major vote of confidence from the global life sciences community in 2017, ...
- Source: drugdu
- 75
- August 9, 2024
CNS-Focused Rapport Therapeutics Preps IPO to Back Phase 2-Ready Epilepsy Drug

Rapport Therapeutics’ lead program could offer more targeted epilepsy treatment compared to currently available anti-seizure medications, which introduce many side effects. The IPO will support plans to develop the oral small molecule in focal epilepsy as well as chronic pain and bipolar disorder. By Frank VinluanRapport Therapeutics, a young biotech company with technology from the labs of Johnson & Johnson, is now preparing to enter the public markets to finance clinical research for a lead program that could help patients whose epilepsy doesn’t respond to currently available anti-seizure medications. Rapport’s IPO paperwork filed with securities regulators late Friday does not yet specify how many shares it plans to offer and in what price range. IPO research firm Renaissance Capital has penciled in a $100 million placeholder figure for the proposed stock offering. The biotech company, which is headquartered in Boston and maintains additional office and lab space in San Diego, ...
- Source: drugdu
- 81
- May 21, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.